187 related articles for article (PubMed ID: 35187781)
1. A randomized, controlled, split-face study of botulinum toxin and broadband light for the treatment of erythematotelangiectatic rosacea.
Tong Y; Luo W; Gao Y; Liu L; Tang Q; Wa Q
Dermatol Ther; 2022 May; 35(5):e15395. PubMed ID: 35187781
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Skin Physiology Change and Safety After Intradermal Injections With Botulinum Toxin: A Randomized, Double-Blind, Placebo-Controlled, Split-Face Pilot Study in Rosacea Patients With Facial Erythema.
Kim MJ; Kim JH; Cheon HI; Hur MS; Han SH; Lee YW; Choe YB; Ahn KJ
Dermatol Surg; 2019 Sep; 45(9):1155-1162. PubMed ID: 30730346
[TBL] [Abstract][Full Text] [Related]
3. Pulsed dye laser followed by intradermal botulinum toxin type-A in the treatment of rosacea-associated erythema and flushing.
Al-Niaimi F; Glagoleva E; Araviiskaia E
Dermatol Ther; 2020 Nov; 33(6):e13976. PubMed ID: 32633449
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin for the treatment of refractory erythema and flushing of rosacea.
Park KY; Hyun MY; Jeong SY; Kim BJ; Kim MN; Hong CK
Dermatology; 2015; 230(4):299-301. PubMed ID: 25765295
[TBL] [Abstract][Full Text] [Related]
5. The toxic edge-A novel treatment for refractory erythema and flushing of rosacea.
Friedman O; Koren A; Niv R; Mehrabi JN; Artzi O
Lasers Surg Med; 2019 Apr; 51(4):325-331. PubMed ID: 30311683
[TBL] [Abstract][Full Text] [Related]
6. Treating rosacea with botulism toxin: Protocol for a systematic review and meta-analysis.
He G; Yang Q; Wu J; Huang Y; Zheng H; Cheng H
J Cosmet Dermatol; 2024 Jan; 23(1):44-61. PubMed ID: 37605478
[TBL] [Abstract][Full Text] [Related]
7. Botulinum Toxin A Alleviates Persistent Erythema and Flushing in Patients with Erythema Telangiectasia Rosacea.
Yang R; Liu C; Liu W; Luo J; Cheng S; Mu X
Dermatol Ther (Heidelb); 2022 Oct; 12(10):2285-2294. PubMed ID: 35925473
[TBL] [Abstract][Full Text] [Related]
8. A split-face study using botulinum toxin type B to decrease facial erythema index.
Oh YJ; Lee NY; Suh DH; Koh JS; Lee SJ; Shin MK
J Cosmet Laser Ther; 2011 Oct; 13(5):243-8. PubMed ID: 21848448
[TBL] [Abstract][Full Text] [Related]
9. A Pilot Study to Evaluate the Efficacy and Safety of Treatment with Botulinum Toxin in Patients with Recalcitrant and Persistent Erythematotelangiectatic Rosacea.
Park KY; Kwon HJ; Kim JM; Jeong GJ; Kim BJ; Seo SJ; Kim MN
Ann Dermatol; 2018 Dec; 30(6):688-693. PubMed ID: 33911508
[TBL] [Abstract][Full Text] [Related]
10. Facial flushing and erythema of rosacea improved by carvedilol.
Seo BH; Kim DH; Suh HS; Choi YS
Dermatol Ther; 2020 Nov; 33(6):e14520. PubMed ID: 33174351
[TBL] [Abstract][Full Text] [Related]
11. Erenumab for Treatment of Persistent Erythema and Flushing in Rosacea: A Nonrandomized Controlled Trial.
Wienholtz NKF; Christensen CE; Do TP; Frifelt LEW; Snellman J; Lopez-Lopez CL; Egeberg A; Thyssen JP; Ashina M
JAMA Dermatol; 2024 Jun; 160(6):612-619. PubMed ID: 38630457
[TBL] [Abstract][Full Text] [Related]
12. Intradermal Botulinum Toxin A Injection for Scalp Sebum Secretion Regulation: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Prospective Study in Chinese Subjects.
Li Y; Chen X; Luo X; Li L; Lin Y
Aesthet Surg J; 2023 Jan; 43(1):NP38-NP48. PubMed ID: 36004504
[TBL] [Abstract][Full Text] [Related]
13. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea.
Bloom BS; Payongayong L; Mourin A; Goldberg DJ
Dermatol Surg; 2015 Jan; 41 Suppl 1():S9-16. PubMed ID: 25548852
[TBL] [Abstract][Full Text] [Related]
14. A new treatment regimen for rosacea: onabotulinumtoxinA.
Dayan SH; Pritzker RN; Arkins JP
J Drugs Dermatol; 2012 Dec; 11(12):e76-9. PubMed ID: 23377526
[TBL] [Abstract][Full Text] [Related]
15. The effect of full-face broadband light treatments alone and in combination with bilateral crow's feet Botulinum toxin type A chemodenervation.
Carruthers J; Carruthers A
Dermatol Surg; 2004 Mar; 30(3):355-66; discussion 366. PubMed ID: 15008861
[TBL] [Abstract][Full Text] [Related]
16. Botulinum Toxin: An Effective Treatment for Flushing and Persistent Erythema in Rosacea.
Luque A; Rojas AP; Ortiz-Florez A; Perez-Bernal J
J Clin Aesthet Dermatol; 2021 Mar; 14(3):42-45. PubMed ID: 33841616
[TBL] [Abstract][Full Text] [Related]
17. The Efficacy and Safety of Fractional CO₂ Laser Combined with Topical Type A Botulinum Toxin for Facial Rejuvenation: A Randomized Controlled Split-Face Study.
Zhu J; Ji X; Li M; Chen XE; Liu J; Zhang JA; Luo D; Zhou BR
Biomed Res Int; 2016; 2016():3853754. PubMed ID: 26998485
[TBL] [Abstract][Full Text] [Related]
18. Treatment of erythemato-telangiectatic rosacea with brimonidine alone or combined with vascular laser based on preliminary instrumental evaluation of the vascular component.
Micali G; Dall'Oglio F; Verzì AE; Luppino I; Bhatt K; Lacarrubba F
Lasers Med Sci; 2018 Aug; 33(6):1397-1400. PubMed ID: 28889348
[TBL] [Abstract][Full Text] [Related]
19. Paroxetine is an effective treatment for refractory erythema of rosacea: Primary results from the Prospective Rosacea Refractory Erythema Randomized Clinical Trial.
Wang B; Huang Y; Tang Y; Zhao Z; Shi W; Jian D; Liu F; Gao Q; Wang P; Yang J; Li L; Xie H; Li J
J Am Acad Dermatol; 2023 Jun; 88(6):1300-1307. PubMed ID: 36806645
[TBL] [Abstract][Full Text] [Related]
20. Use of beta-blockers for rosacea-associated facial erythema and flushing: A systematic review and update on proposed mode of action.
Logger JGM; Olydam JI; Driessen RJB
J Am Acad Dermatol; 2020 Oct; 83(4):1088-1097. PubMed ID: 32360760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
